September 2021
Mesoblast says FDA has not put a ‘hold’ on drug trial
The biotech’s shares fell further on Wednesday as investor concerns increased over the delay in a trial for its key product.
August 2021
Mesoblast shares dive 16pc as FDA raises more questions
The biotech’s losses for the 2021 full year widened and it admitted that it will need more cash to keep running.
Mesoblast loses its CFO
Josh Muntner will leave on August 30 after 3½ years with the Melbourne-based biotech, but no reason was provided for his departure.
July 2021
Mesoblast boss won’t answer share deal questions
The biotech’s chief executive will not be fielding queries over a reconciliation gap of up to 27.7 million stocks in a previous contract.
Mesoblast, Grünenthal downgrade partnership deal
The payments the Melbourne-based biotech will receive if certain milestones are met have been slashed by about $37.5 million.
April 2021
Mesoblast may face fresh class action claim in Australia
Specialist class action firm Phi Finney McDonald is preparing a class action against the biotech alleging misleading or deceptive conduct to investors and breaches of its continuous disclosure obligations.
March 2021
Mesoblast gets a lifeline via $138m finance deal
The stem cell company won the backing of US-based investor group, SurgCenter Development, allowing it to keep operating.
February 2021
Mesoblast ‘excited’ by back pain trial results
Despite the mixed results, the regenerative medicine company plans to engage with the powerful US regulator after delivering the late results of its highly anticipated back pain trial.
December 2020
Mesoblast shares smashed on Revascor trial results
The stock tumbled more than 15 per cent after the stem cell therapy group missed its primary end point in a trial of its chronic heart failure treatment.
August 2020
Mesoblast scores US regulatory breakthrough
Mesoblast has scored a win in marketing its stem cell therapy drug in the US after a verdict was delivered on Friday morning.
Mesoblast shares tumble again as investors pre-empt FDA
The biotech's management team will argue the case for approval of its cellular therapy at a make-or-break meeting with the FDA on Thursday.
June 2020
Mesoblast re-enters ASX 200 after wild two decade ride
Investors are split whether the stem cell company is a blue-chip of tomorrow or a cash drain.
May 2020
Mesoblast completes $138m fundraising
Proceeds will be used to scale-up manufacturing of the company’s lead product candidate for the treatment of critically ill COVID-19 patients.